Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

The advantages and limitations of impedance aggregometry in detection of heparin-induced thrombocytopenia

L Slavik, G Svobodova, J Ulehlova, V Krcova, A Hlusi, J Prochazkova, M Kaletova, Y Hrckova, K Indrak

. 2014 ; 60 (8) : 1319-1324.

Jazyk angličtina Země Německo

Perzistentní odkaz   https://www.medvik.cz/link/bmc18034623

Grantová podpora
NT14394 MZ0 CEP - Centrální evidence projektů

BACKGROUND: Heparin-induced thrombocytopenia (HIT) represents a serious complication of heparin treatment. IgG antibodies binding platelet factor 4 (PF4) and heparin trigger the clinical manifestations of HIT. However, only a portion of the antibodies have the ability to activate platelets, and these can be identified by a platelet aggregation test (functional testing). Current methods HIPA and SRA are time-consuming and difficult if HIT is clinically suspected; therefore, numerous new methods have recently been developed. METHODS: To determine HIT, impedance aggregometry using the Multiplate analyzer (MEA) as heparin-induced aggregation techniques and the Technozym HIT Ig ELISA test were used. The MEA method uses sensitization of donor platelets with patient plasma in the presence of heparin at a concentration of 0.5 IU/mL. The results were compared with the ELISA test. RESULTS: We examined 190 patients at clinically intermediate and higher risk of HIT according to the 4T score. All samples were examined by the ELISA test and MEA, with positive samples being further confirmed by high-concentration heparin. The methodology was modified with respect to the dilution for high positive samples and assessment has been extended to an index of inhibition. CONCLUSIONS: In the studied group, we demonstrated that MEA has sufficient sensitivity and higher specificity. In the group of patients, 10.0% showed positive results by MEA as compared with 7.3% determined by ELISA. Unlike the ELISA methods of the same quality, MEA is more suitable for detecting platelet-activating HIT antibodies in practice.

000      
00000naa a2200000 a 4500
001      
bmc18034623
003      
CZ-PrNML
005      
20190104103845.0
007      
ta
008      
181011s2014 gw f 000 0|eng||
009      
AR
035    __
$a (PubMed)25185417
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Slavík, Luděk $7 xx0081908 $u Department of Hemato-Oncology, Palacký University Faculty of Medicine and Dentistry and University Hospital Olomouc, Czech Republic
245    14
$a The advantages and limitations of impedance aggregometry in detection of heparin-induced thrombocytopenia / $c L Slavik, G Svobodova, J Ulehlova, V Krcova, A Hlusi, J Prochazkova, M Kaletova, Y Hrckova, K Indrak
520    9_
$a BACKGROUND: Heparin-induced thrombocytopenia (HIT) represents a serious complication of heparin treatment. IgG antibodies binding platelet factor 4 (PF4) and heparin trigger the clinical manifestations of HIT. However, only a portion of the antibodies have the ability to activate platelets, and these can be identified by a platelet aggregation test (functional testing). Current methods HIPA and SRA are time-consuming and difficult if HIT is clinically suspected; therefore, numerous new methods have recently been developed. METHODS: To determine HIT, impedance aggregometry using the Multiplate analyzer (MEA) as heparin-induced aggregation techniques and the Technozym HIT Ig ELISA test were used. The MEA method uses sensitization of donor platelets with patient plasma in the presence of heparin at a concentration of 0.5 IU/mL. The results were compared with the ELISA test. RESULTS: We examined 190 patients at clinically intermediate and higher risk of HIT according to the 4T score. All samples were examined by the ELISA test and MEA, with positive samples being further confirmed by high-concentration heparin. The methodology was modified with respect to the dilution for high positive samples and assessment has been extended to an index of inhibition. CONCLUSIONS: In the studied group, we demonstrated that MEA has sufficient sensitivity and higher specificity. In the group of patients, 10.0% showed positive results by MEA as compared with 7.3% determined by ELISA. Unlike the ELISA methods of the same quality, MEA is more suitable for detecting platelet-activating HIT antibodies in practice.
590    __
$a bohemika - dle Pubmed
650    02
$a senioři $7 D000368
650    02
$a trombocyty $7 D001792
650    02
$a elektrická impedance $7 D017097
650    02
$a ELISA $7 D004797
650    02
$a ženské pohlaví $7 D005260
650    12
$a heparin $x chemie $x škodlivé účinky $7 D006493
650    02
$a lidé $7 D006801
650    02
$a imunoglobulin G $x chemie $7 D007074
650    02
$a mužské pohlaví $7 D008297
650    02
$a Middle Aged
650    12
$a agregace trombocytů $x účinky léků $7 D010974
650    02
$a vyšetření funkce trombocytů $7 D010979
650    02
$a pravděpodobnost $7 D011336
650    02
$a reprodukovatelnost výsledků $7 D015203
650    02
$a senzitivita a specificita $7 D012680
650    02
$a statická elektřina $7 D055672
650    12
$a trombocytopenie $x chemicky indukované $7 D013921
700    1_
$a Svobodová, Gabriela, $d 1988- $7 xx0224773 $u Department of Hemato-Oncology, Palacký University Faculty of Medicine and Dentistry and University Hospital Olomouc, Czech Republic
700    1_
$a Úlehlová, Jana $u Department of Hemato-Oncology, Palacký University Faculty of Medicine and Dentistry and University Hospital Olomouc, Czech Republic $7 xx0117725
700    1_
$a Krčová, Věra, $d 1934- $7 nlk19990073440 $u Department of Hemato-Oncology, Palacký University Faculty of Medicine and Dentistry and University Hospital Olomouc, Czech Republic
700    1_
$a Hluší, Antonín $7 xx0074065 $u Department of Hemato-Oncology, Palacký University Faculty of Medicine and Dentistry and University Hospital Olomouc, Czech Republic
700    1_
$a Procházková, Jana $7 xx0067433 $u Department of Hemato-Oncology, Palacký University Faculty of Medicine and Dentistry and University Hospital Olomouc, Czech Republic
700    1_
$a Kaletová, Markéta $7 xx0097230 $u Department of Internal Medocine 1 - Cardiology, Palacký University Faculty of Medicine and Dentistry and University Hospital Olomouc, Czech Republic
700    1_
$a Hrčková, Yvona $7 xx0076929 $u Department of Internal Medocine 1 - Cardiology, Palacký University Faculty of Medicine and Dentistry and University Hospital Olomouc, Czech Republic
700    1_
$a Indrák, Karel, $d 1947- $7 jn20000401162 $u Department of Hemato-Oncology, Palacký University Faculty of Medicine and Dentistry and University Hospital Olomouc, Czech Republic
773    0_
$t Clinical Laboratory $x 1433-6510 $g Roč. 60, č. 8 (2014), s. 1319-1324 $p Clin Lab $w MED00009480
773    0_
$p Clin Lab $g 60(8):1319-24, 2014 $x 1433-6510
910    __
$a ABA008 $y 4 $z 0
990    __
$a 20181011145941 $b ABA008
991    __
$a 20190104104040 $b ABA008
999    __
$a ok $b bmc $g 1341477 $s 1031620
BAS    __
$a 3
BMC    __
$a 2014 $b 60 $c 8 $d 1319-1324 $x MED00009480 $i 1433-6510 $m Clinical laboratory
GRA    __
$a NT14394 $p MZ0
LZP    __
$a NLK 2018/lp

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...